Paving the way for anti-Abeta active immunotherapy
European Pharmaceutical Review
SEPTEMBER 22, 2023
Re-engineering proteins to develop novel immunotherapies AV-1959D from Nuravax is a DNA-based therapeutic, containing Abeta1-11 sequence bound to multiple T-cell helper epitopes. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed.
76 
Let's personalize your content